Accurate diagnostics with precision biomarkers
Genetic biomarkers are particularly useful for diagnoses and therapeutics. However, most approved drugs have a single variant biomarker. Heligenics offers whole gene biomarkers, where diagnosis can be based upon all variants with similar activity to an established biomarker.
Whole gene biomarkers examine all the mutations in a gene rather than a single mutation. This is a natural conceptual expansion of what is already in common clinical practice.
Steady growth in genetic biomarkers over the last decade
There are 100s of genetic biomarkers
Genes have many variants with the same activity as known biomarkers
Whole gene biomarkers expand the number of customers eligible for a drug
Drug resistance mutations for a whole gene are useful
Why use one genotype when you can use a whole gene biomarker?
Treatments based on one genetic marker have medical advantages
46% of total recent approvals
One mutation as a biomarker
From “The Personalized Medicine Report: 2017 Opportunity, Challenges, and the Future”.
One Size Does Not Fit All
Percentage of the patient population for which a particular drug is NOT effective
Anti-Depressants (SSRIs) 38%
Asthma Drugs 40%
Diabetes Drugs 43%
Arthritis Drugs 50%
Alsheimer’s Drugs 70%
Cancer Drugs 75%
Whole Gene Biomarker
Example of patients with single mutation biomarker identified versus using MEGA-Map™ whole gene biomarker panel
MEGA-Map™ Whole Gene Biomarker
Disease, but lack Single
Disease with Whole Gene
Disease with Single Mutation